← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 3.1% below its 1-year high (as of 2026-09-16). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 7.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
TDWD
Tailwind 2.0 Acquisition Corp.
Valuation N/A
Financial Services
Price$10.11
Model IV—
P/IV—
Limited data — see page
TDWDR
Tailwind 2.0 Acquisition Corp.
Valuation N/A
Financial Services
Price$0.12
Model IV—
P/IV—
Limited data — see page
TDWDU
Tailwind 2.0 Acquisition Corp.
Valuation N/A
Financial Services
Price$10.15
Model IV—
P/IV—
Limited data — see page
TEAM
Atlassian Corp
Valuation N/A
Technology Risk 44 · Elevated
Price$179.70
Model IV—
P/IV—
Market implies +61.6%/yr vs model +21.6% · above model
TECK
TECK RESOURCES LTD
Valuation N/A
Basic Materials
Price$66.44
Model IV—
P/IV—
Limited data — see page
TECX
Tectonic Therapeutic, Inc.
Valuation N/A
Healthcare Risk 43 · Elevated
Price$29.05
Model IV—
P/IV—
Limited data — see page
TEI
TEMPLETON EMERGING MARKETS INCOME FUND
Valuation N/A
Unknown
Price$6.63
Model IV—
P/IV—
Limited data — see page
TELO
Telomir Pharmaceuticals, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$1.17
Model IV—
P/IV—
Limited data — see page
TEM
Tempus AI, Inc.
Valuation N/A
Technology Risk 36 · Moderate
Price$59.01
Model IV—
P/IV—
Market implies -50.0%/yr vs model +50.0% · below model
TENX
TENAX THERAPEUTICS, INC.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$1.86
Model IV—
P/IV—
Limited data — see page
TEO
TELECOM ARGENTINA SA
Valuation N/A
Communication Services
Price$13.80
Model IV—
P/IV—
Limited data — see page
TER
TERADYNE, INC
Valuation N/A
Healthcare Risk 47 · Elevated
Price$332.85
Model IV—
P/IV—
Market implies +49.3%/yr vs model +2.0% · above model
TFII
TFI International Inc.
Valuation N/A
Industrials Risk 27 · Moderate
Price$133.29
Model IV—
P/IV—
Limited data — see page
TGB
TASEKO MINES LTD
Valuation N/A
Basic Materials Risk 32 · Moderate
Price$7.84
Model IV—
P/IV—
Limited data — see page
TGE
Generation Essentials Group
Valuation N/A
Communication Services
Price$0.89
Model IV—
P/IV—
Limited data — see page
TGEN
TECOGEN INC.
Valuation N/A
Industrials Risk 35 · Moderate
Price$3.05
Model IV—
P/IV—
Market implies +27.2%/yr vs model +2.6% · above model
TGHL
GrowHub Ltd
Valuation N/A
Technology Risk 31 · Moderate
Price$0.95
Model IV—
P/IV—
Market implies +55.3%/yr vs model +15.0% · above model
TGL
TREASURE GLOBAL INC
Valuation N/A
Technology Risk 33 · Moderate
Price$2.73
Model IV—
P/IV—
Market implies +32.8%/yr vs model +2.0% · above model
THC
TENET HEALTHCARE CORP
Valuation N/A
Healthcare Risk 34 · Moderate
Price$260.85
Model IV—
P/IV—
Market implies -6.1%/yr vs model +8.6% · below model
THCH
TH International Ltd
Valuation N/A
Consumer Cyclical Risk 35 · Moderate
Price$1.36
Model IV—
P/IV—
Limited data — see page
THH
TryHard Holdings Ltd
Valuation N/A
Communication Services
Price$1.67
Model IV—
P/IV—
Limited data — see page
THM
INTERNATIONAL TOWER HILL MINES LTD
Valuation N/A
Basic Materials Risk 31 · Moderate
Price$2.40
Model IV—
P/IV—
Market implies +55.8%/yr vs model +5.0% · above model
THQ
abrdn Healthcare Opportunities Fund
Valuation N/A
Unknown
Price$18.92
Model IV—
P/IV—
Limited data — see page
THW
abrdn World Healthcare Fund
Valuation N/A
Unknown
Price$13.39
Model IV—
P/IV—
Limited data — see page
THYP
21Shares Hyperliquid ETF
Valuation N/A
Financial Services Risk 51 · Elevated
Price$46.82
Model IV—
P/IV—
Limited data — see page
TIGO
MILLICOM INTERNATIONAL CELLULAR SA
Valuation N/A
Communication Services Risk 41 · Elevated
Price$95.82
Model IV—
P/IV—
Limited data — see page
TII
Titan Mining Corp
Valuation N/A
Basic Materials Risk 35 · Moderate
Price$2.95
Model IV—
P/IV—
Limited data — see page
TIL
Instil Bio, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$7.38
Model IV—
P/IV—
Limited data — see page
TJGC
TJGC GROUP Ltd
Valuation N/A
Technology Risk 37 · Moderate
Price$11.19
Model IV—
P/IV—
Market implies +69.1%/yr vs model +15.0% · above model
TKC
TURKCELL ILETISIM HIZMETLERI A S
Valuation N/A
Communication Services Risk 45 · Elevated
Price$5.37
Model IV—
P/IV—
Limited data — see page
TKNO
Alpha Teknova, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$6.71
Model IV—
P/IV—
Market implies +47.0%/yr vs model +2.4% · above model
TLK
PERUSAHAAN PERSEROAN PERSERO PT TELEKOMUNIKASI INDONESIA TBK
Valuation N/A
Communication Services
Price$14.94
Model IV—
P/IV—
Limited data — see page
TLNC
Talon Capital Corp.
Valuation N/A
Financial Services
Price$10.25
Model IV—
P/IV—
Limited data — see page
TLNCU
Talon Capital Corp.
Valuation N/A
Financial Services
Price$10.50
Model IV—
P/IV—
Limited data — see page
TLNCW
Talon Capital Corp.
Valuation N/A
Financial Services
Price$0.70
Model IV—
P/IV—
Limited data — see page
TLPH
TALPHERA, INC.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$1.24
Model IV—
P/IV—
Market implies +119.8%/yr vs model +2.0% · above model
TLRY
Tilray Brands, Inc.
Valuation N/A
Healthcare Risk 28 · Moderate
Price$4.02
Model IV—
P/IV—
Market implies +29.1%/yr vs model +12.5% · above model
TLSA
Tiziana Life Sciences Ltd
Valuation N/A
Healthcare Risk 27 · Moderate
Price$0.96
Model IV—
P/IV—
Limited data — see page
TLX
Telix Pharmaceuticals Ltd
Valuation N/A
Healthcare Risk 35 · Moderate
Price$11.29
Model IV—
P/IV—
Limited data — see page
TMC
TMC the metals Co Inc.
Valuation N/A
Basic Materials Risk 27 · Moderate
Price$3.94
Model IV—
P/IV—
Market implies +65.5%/yr vs model +5.0% · above model
TMCR
Metals Royalty Co Inc.
Valuation N/A
Basic Materials Risk 62 · High
Price$5.65
Model IV—
P/IV—
Limited data — see page
TMDE
TMD Energy Ltd
Valuation N/A
Consumer Defensive Risk 31 · Moderate
Price$0.75
Model IV—
P/IV—
Market implies -50.0%/yr vs model +2.0% · below model
TME
Tencent Music Entertainment Group
Valuation N/A
Communication Services Risk 52 · Elevated
Price$8.11
Model IV—
P/IV—
Limited data — see page
TMQ
Trilogy Metals Inc.
Valuation N/A
Basic Materials Risk 43 · Elevated
Price$3.27
Model IV—
P/IV—
Market implies +50.7%/yr vs model +5.0% · above model
TMTS
Spartacus Acquisition Corp. II
Valuation N/A
Financial Services
Price$10.06
Model IV—
P/IV—
Limited data — see page
TMTSU
Spartacus Acquisition Corp. II
Valuation N/A
Financial Services
Price$10.30
Model IV—
P/IV—
Limited data — see page
TNGX
Tango Therapeutics, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$23.89
Model IV—
P/IV—
Market implies +46.9%/yr vs model +13.9% · above model
TNMG
TNL Mediagene
Valuation N/A
Technology Risk 28 · Moderate
Price$3.36
Model IV—
P/IV—
Limited data — see page
TNON
Tenon Medical, Inc.
Valuation N/A
Healthcare Risk 41 · Elevated
Price$5.93
Model IV—
P/IV—
Limited data — see page
TNXP
Tonix Pharmaceuticals Holding Corp.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$11.87
Model IV—
P/IV—
Market implies +47.7%/yr vs model +15.0% · above model
TNYA
Tenaya Therapeutics, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$0.64
Model IV—
P/IV—
Limited data — see page
TOIIW
Oncology Institute, Inc.
Valuation N/A
Healthcare Risk 57 · Elevated
Price$0.05
Model IV—
P/IV—
Market implies -50.0%/yr vs model +25.5% · below model
TOMZ
TOMI Environmental Solutions, Inc.
Valuation N/A
Basic Materials Risk 49 · Elevated
Price$1.62
Model IV—
P/IV—
Market implies +29.7%/yr vs model +0.0% · above model
TONX
TON Strategy Co
Valuation N/A
Financial Services Risk 29 · Moderate
Price$3.04
Model IV—
P/IV—
Market implies +89.7%/yr vs model +5.0% · above model
TOP
TOP Financial Group Ltd
Valuation N/A
Financial Services Risk 28 · Moderate
Price$14.88
Model IV—
P/IV—
Market implies +87.7%/yr vs model +2.0% · above model
TOPP
Toppoint Holdings Inc.
Valuation N/A
Industrials Risk 48 · Elevated
Price$0.16
Model IV—
P/IV—
Market implies -20.3%/yr vs model +2.0% · below model
TORO
TORO CORP.
Valuation N/A
Industrials Risk 34 · Moderate
Price$6.42
Model IV—
P/IV—
Market implies +70.7%/yr vs model +15.0% · above model
TOUR
Tuniu Corp
Valuation N/A
Industrials Risk 43 · Elevated
Price$5.11
Model IV—
P/IV—
Market implies +48.6%/yr vs model +5.4% · above model
TOVX
Theriva Biologics, Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$0.25
Model IV—
P/IV—
Limited data — see page
TPL
Texas Pacific Land Corp
Valuation N/A
Financial Services Risk 52 · Elevated
Price$371.63
Model IV—
P/IV—
Limited data — see page